title: Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
abstract: Current treatment of metastatic breast cancer (MBC) aims at achieving meaningful clinical responses, improved quality of life, long-term remissions, prolonged survival, and dares to hope for a cure in a small percentage of cases. This article will discuss both consensus and controversies in the management of MBC in the context of the new evolving breast cancer molecular classification. Hormonal therapy remains the mainstay of management of MBC Luminal A and B. Data is emerging on management of ErbB2-positive HR-positive MBC by combining hormonal manipulation and targeted anti-ErbB2 therapy and has recently received regulatory approval in Europe and USA. The optimal use and duration of single agent or combination chemotherapy is discussed. Data and controversies surrounding the use of newer agents such as nab-paclitaxel, ixabepilone, eribulin, and PARP inhibitors as well as trastuzumab is reviewed. Better understanding of pathophysiology has paved the way for the introduction of newer anti-ErbB2 agents such as lapatinib, pertuzumab, T-DM1 and neratinib. Controversies regarding bevacizumab and anti-angiogenesis are discussed. Bisphosphonates have significantly reduced skeletal related events and made significant improvements in the quality of life of patients with MBC. Newer anti-RANK Ligand antibodies show promising results. Significant advances in the understanding of molecular biology of breast cancer have been made and should lead to an improvement in the outcome of MBC. More possibilities of cure can become an attainable goal in the near future.
authors.affiliation: Breast Center of Excellence, NK Basile Cancer Institute, American University of Beirut Medical Center, Riad El-Solh, Beirut, Lebanon.
authors.forename: Nagi S
authors.initials: NS
authors.lastname: El Saghir
authors.forename: Arafat
authors.initials: A
authors.lastname: Tfayli
authors.forename: Hassan A
authors.initials: HA
authors.lastname: Hatoum
authors.forename: Zahi
authors.initials: Z
authors.lastname: Nachef
authors.forename: Phuong
authors.initials: P
authors.lastname: Dinh
authors.forename: Ahmad
authors.initials: A
authors.lastname: Awada
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000145:classification / Q000556:secondary* / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D010166:Palliative Care; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011379:Prognosis; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D066246:ErbB Receptors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D053245:RANK Ligand; D018719:Erb-b2 Receptor Tyrosine Kinases